CVS Health (NYSE:CVS) Releases FY 2025 Earnings Guidance

CVS Health (NYSE:CVS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 5.750-6.000 for the period, compared to the consensus EPS estimate of 5.970. The company issued revenue guidance of -.

CVS Health Trading Up 3.4 %

Shares of CVS traded up $2.16 during midday trading on Thursday, hitting $65.38. 2,507,002 shares of the stock were exchanged, compared to its average volume of 12,887,452. CVS Health has a 52-week low of $43.56 and a 52-week high of $80.75. The stock has a fifty day simple moving average of $50.71 and a 200 day simple moving average of $55.94. The firm has a market cap of $82.27 billion, a P/E ratio of 16.57, a P/E/G ratio of 0.60 and a beta of 0.61. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. On average, research analysts anticipate that CVS Health will post 5.14 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 4.07%. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CVS shares. Barclays raised their price target on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday. Wells Fargo & Company upgraded CVS Health from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $60.00 to $66.00 in a research report on Monday, November 18th. Cantor Fitzgerald upgraded CVS Health from a “neutral” rating to an “overweight” rating in a research note on Wednesday. Royal Bank of Canada dropped their price target on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Finally, Truist Financial raised their price target on CVS Health from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $69.89.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.